EvolutionaryScale

New York, NY AI / Life Sciences Acquired

EvolutionaryScale is a frontier AI research lab building large generative language models for biology. Spun out of Meta's FAIR protein team in 2023, the company developed the ESM (Evolutionary Scale Modeling) family of protein language models, culminating in ESM3, a multimodal generative model trained on 2.78 billion protein sequences that jointly reasons over protein sequence, structure, and function. ESM3 was used to generate a novel green fluorescent protein representing the equivalent of roughly 500 million years of natural evolution. The company emerged from stealth in June 2024 with a $142M seed round led by Nat Friedman, Daniel Gross, and Lux Capital with participation from Amazon and NVIDIA's NVentures. In November 2025, EvolutionaryScale was acquired by Chan Zuckerberg Biohub as part of the Chan Zuckerberg Initiative's restructuring around an AI-x-biology mission, with co-founder Alex Rives becoming Head of Science at CZI.

Acquired

EvolutionaryScale has been acquired

Acquired by Chan Zuckerberg Biohub / Chan Zuckerberg Initiative November 6, 2025

This company is no longer available on our private secondary market.

Overview

Company data and valuation marks are estimates and may be incomplete, stale, erroneous, or revised.

Founded

2023

Employees

40–60

Total Funding

$142M

1 rounds

Funding

Total raised $142M across 1 rounds

Funding data and valuation marks are estimates and may be incomplete, stale, erroneous, or revised.

Last updated 06-25-2026

Latest Round

Type

Seed

Date

June 25, 2024

Amount

$142M

Valuation

Lead Investors

Nat Friedman & Daniel Gross, Lux Capital

Prominent Investors

Nat Friedman Daniel Gross Lux Capital Amazon Web Services (AWS) Nventures

Leadership

  • Alexander Rives

    Co-Founder & CEO / Chief Scientist

  • Tom Sercu

    Co-Founder & VP of Engineering

  • Salvatore Candido

    Co-Founder & COO

  • Roshan Rao

    Co-Founder

  • Thomas Hayes

    Co-Founder

  • Halil Akin

    Co-Founder

Competitors

Competitor list is illustrative and may be incomplete, stale, or erroneous.

  • Isomorphic Labs

    Alphabet/DeepMind spin-out applying AlphaFold-derived AI models to drug discovery; partnerships with Eli Lilly and Novartis.

  • Cradle Bio

    Protein engineering platform using ML to design improved protein variants for therapeutics, enzymes, vaccines, peptides, and antibodies.

  • Profluent

    AI-first protein design startup developing foundation models and 'scaling laws' for biology; products include OpenCRISPR and OpenAntibodies.

  • Latent Labs

    AI biotech founded by DeepMind/AlphaFold alumni building web-based generative protein design models.

  • Inceptive

    AI-driven biological software company designing RNA molecules and therapeutics using deep learning.

  • Ginkgo Bioworks

    Synthetic biology platform with growing AI-for-biology capabilities including foundation models for protein and DNA design.

Access live market data

Sign Up

Data collected with AI, which can make mistakes. Please double-check this information.